Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.7636 |
---|---|
High | 0.7736 |
Low | 0.6956 |
Bid | 0.7197 |
Offer | 0.7292 |
Previous close | 0.7681 |
Average volume | 781.61k |
---|---|
Shares outstanding | 119.44m |
Free float | 97.74m |
P/E (TTM) | -- |
Market cap | 83.59m USD |
EPS (TTM) | -1.95 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
- Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
- Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
- Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
- Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
- Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
- Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
- Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
- Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
More ▼